Research in the early 1960s showed that in rats, administration of α-MSH caused sexual arousal, and work on this continued in many labs up through the 1980s, when scientists at the University of Arizona began attempting to develop α-MSH and analogs as potential
sunless tanning agents, and synthesized and tested several analogs, including
melanotan-I and melanotan II. Early in the research process one of the scientists, who was conducting experiments on himself with an early tool compound, melanotan II, injected himself with twice the dose he intended to and got an eight-hour erection, along with nausea and vomiting. which changed its name to Clinuvel in 2006. Afamelanotide was approved by the FDA in 2019. Competitive Technologies sued Palatin for breach of contract and tried to claim ownership of bremelanotide; the parties settled in 2008 with Palatin retaining rights to bremelanotide, returning rights to melanotan II to Competitive Technologies, and paying US$800,000. Melanotan-II may cause reversible darkening of moles and freckles. It is unclear if Melanotan II can increase (or reduce) the risk of developing
melanoma. Reports of melanomas associated with the use of Melanotan II have coincided with heavy sunbathing and sun bed use. A 2019 study showed Melanotan-II having improved sociability deficits in mice exhibiting autistic features. ==Society and culture==